Literature DB >> 21502555

Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.

Takashi Kijima1, Tomohito Shimizu, Shinpei Nonen, Mitsugi Furukawa, Yasushi Otani, Toshiyuki Minami, Ryo Takahashi, Haruhiko Hirata, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Sho Goya, Yasushi Fujio, Junichi Azuma, Isao Tachibana, Ichiro Kawase.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21502555     DOI： 10.1200/JCO.2010.34.3368

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

1.  A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma.

Authors:  Tomohiro Kaneko; Akira Shimizu; Michiko Aoki; Shuichi Tsuruoka
Journal:  CEN Case Rep       Date:  2014-07-18

Review 2.  Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

3.  Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.

Authors:  Hiroto Ueda; Hidetoshi Hayashi; Keita Kudo; Masayuki Takeda; Kazuhiko Nakagawa
Journal:  Invest New Drugs       Date:  2016-08-23       Impact factor: 3.850

4.  Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.

Authors:  Tsukasa Yoshida; Kazuhiko Yamada; Koichi Azuma; Akihiko Kawahara; Hideyuki Abe; Satoshi Hattori; Fumie Yamashita; Yoshiaki Zaizen; Masayoshi Kage; Tomoaki Hoshino
Journal:  Med Oncol       Date:  2012-12-22       Impact factor: 3.064

5.  Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases.

Authors:  Yukihiro Yano; Yoshinobu Namba; Masahide Mori; Yukie Nakazawa; Ayumi Nashi; Shinichi Kagami; Manabu Niinaka; Tsutomu Yoneda; Hiromi Kimura; Toshihiko Yamaguchi; Soichiro Yokota
Journal:  Lung Cancer Int       Date:  2012-11-08

Review 6.  Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.

Authors:  Yosuke Togashi; Hidetoshi Hayashi; Kazuhiko Nakagawa; Kazuto Nishio
Journal:  Drug Des Devel Ther       Date:  2014-07-31       Impact factor: 4.162

7.  Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.

Authors:  Tomohiro Suzumura; Tatsuo Kimura; Shinzoh Kudoh; Kanako Umekawa; Misato Nagata; Kuniomi Matsuura; Hidenori Tanaka; Shigeki Mitsuoka; Naruo Yoshimura; Yukimi Kira; Toshiyuki Nakai; Kazuto Hirata
Journal:  BMC Cancer       Date:  2012-12-04       Impact factor: 4.430

8.  The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.

Authors:  Shuang Xin; Yuanyuan Zhao; Xueding Wang; Yan Huang; Jing Zhang; Ying Guo; Jiali Li; Hongliang Li; Yuxiang Ma; Lingyan Chen; Zhihuang Hu; Min Huang; Li Zhang
Journal:  Sci Rep       Date:  2015-07-31       Impact factor: 4.379

Review 9.  Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.

Authors:  Jun Ni; Li Zhang
Journal:  Chin Med J (Engl)       Date:  2016-02-05       Impact factor: 2.628

10.  Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.

Authors:  Zhe Wang; Xiaoyu Wang; Zhen Wang; Yuyi Feng; Yaqin Jia; Lili Jiang; Yangliu Xia; Jun Cao; Yong Liu
Journal:  JAMA Netw Open       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.